Manages leukemia, lymphoma, and solid tumor malignancies. ANDA 212363, held by Gland. Allopurinol Sodium.
As of Nov 16, 2026, ANDA 212363 (Allopurinol Sodium), held by Gland, was first approved by FDA on Jan 26, 2022, with 1 approved supplement and 0 published complete response letters.
Allopurinol for injection is indicated for the management of adult and pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 26, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Allopurinol SodiumEQ 500MG BASE/VIAL · injectable;injection | Allopurinol Sodium | Rx |
| Aug 8, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 26, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters